. Capillary endothelial cells (ECs) play a key role in alveolar gas exchange and actively participate in lung repair after acute lung injury (ALI). Acute Respiratory Distress Syndrome (ARDS) is a life- threatening complication of ALI with high mortality rate. Given the lack of major improvements in ALI/ ARDS clinical management, there is a compelling need for innovative molecular approaches to complement existing ALI/ ARDS therapies. My laboratory previously demonstrated that FOXF1 transcription factor is a critical regulator of lung vascular development in mice and humans. Global deletion of Foxf1 gene in mice is embryonic lethal, whereas mice heterozygous for the Foxf1 null allele (Foxf1+/-) had reduced numbers of pulmonary capillaries and increased mortality during the early neonatal period. Inactivating mutations in FOXF1 gene locus were found in >50% of patients with Alveolar Capillary Dysplasia (ACD), a rare congenital disorder with high mortality rate due to severe reduction in pulmonary capillaries. While these studies indicate an important role for FOXF1 in development of pulmonary vasculature, FOXF1 function in adult lung/ injury repair remains unknown. In this proposal, we provide preliminary data demonstrating that FOXF1 levels are reduced after lung injury in mice and humans. Endothelial-specific deletion of both Foxf1 alleles causes respiratory failure and mortality due to loss of endothelial integrity, disruption of adherens junctions and reduced expression of genes critical for EC barrier function. Deletion of only one Foxf1 allele from ECs inhibits lung repair and increases mortality in mouse ALI models. Knockdown of FOXF1 in cultured ECs delays cell entry into S phase, increases levels of cell cycle inhibitors p21cip1 and p15ink4b, and reduces phosphorylation of STAT3, a key transcriptional mediator of endothelial proliferation. FOXF1 physically binds to the STAT3 protein, and mutations in STAT3-binding region of the FOXF1 protein were recently found in ACD patients, emphasizing the importance of FOXF1-STAT3 protein interactions in ECs. In this grant proposal, we will identify molecular mechanisms regulated by FOXF1 during endothelial repair using mouse and rat ALI models. We will test the hypothesis that FOXF1 promotes lung repair after acute lung injury.
In Aim 1, we will use cultured ECs and unique mouse models with gain-of-function and loss-of-function of FOXF1 to determine the role of FOXF1 in EC barrier function and identify direct FOXF1 target genes. We will also use nanoparticles (specifically targeting ECs in vivo) and a small molecule FOXF1-activating compound (recently discovered in my laboratory) to restore FOXF1 expression after lung injury and determine whether pharmacological targeting of FOXF1 will promote endothelial repair.
In Aim 2, we will examine the importance of FOXF1-STAT3 interactions and FOXF1-mediated repression of p21cip1 and p15ink4b for EC proliferation in vitro and in vivo. Completion of our studies will identify novel molecular mechanisms whereby FOXF1 regulates lung repair and determine whether targeting FOXF1 could be beneficial for ALI patients.
. Our grant proposal focuses on novel molecular mechanisms of endothelial repair that are regulated by FOXF1 transcription factor in mouse and rat lung injury models. We will use transgenic mice, novel small molecule compounds and nanoparticles targeting pulmonary endothelial cells to determine whether FOXF1 is required for endothelial repair after lung injury.